A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low- Grade and Anaplastic Ependymoma

Protocol
09-031
Full Title
A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma
Phase
II
Purpose

Temozolomide is a drug designed to kill cancer cells by damaging DNA. It is currently approved for the treatment of brain tumors such asglioblastoma and astrocytoma. Lapatinib is a drug designed to prevent or slow down the growth of cancer cells by blocking proteins inside the cancer cell. It is approved for the treatment of breast cancer.

In this study, investigators want to evaluate the effectiveness of combining temozolomide and lapatinib to treat patients with recurrent ependymoma. Both drugs are taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have recurrent low-grade or anaplastic ependymoma.
  • At least 2 weeks must have passed since major surgery and 4 weeks since completion of chemotherapy or radiation therapy and entry into the study, and patients must have recovered from any side effects.
  • Patients must be age 18 or older.

For more information and to inquire about eligibility for this study, please contact Antonio Omuro at 212-639-7523.

Disease(s)
Brain Tumors, Primary: Other Trials
Pediatric Brain Tumors: Brain Cancer